Paradoxical skin lesions induced by anti-TNF-α agents in SAPHO syndrome.
The objectives of the study were to characterize the clinical picture of paradoxical skin lesions in SAPHO patients treated with anti-TNF-α agents and to explore its pathogenesis. Patients treated with anti-TNF-α therapy were identified from a cohort of 164 SAPHO patients. The clinical data and skin biopsies were collected. The usage, efficacy, and side effects of anti-TNF-α therapy were recorded. Forty-one (25.0%) patients received anti-TNF-α therapy, of which seven (17.1%) developed paradoxical skin lesions after 1 to 14 infusions. Patients with such lesions were older at onset of skin lesions than those without (p = 0.034). Expression of TNF-α in palmoplantar pustulosis increased after anti-TNF-α therapy in the two examined patients with exacerbated skin lesions. Anti-TNF-α therapy induces paradoxical skin lesions in 17.1% SAPHO patients. Late onset of skin manifestations is associated with an increased risk of such lesions. The paradoxical elevation of TNF-α expression in lesions may contribute to this phenomenon.
['Li|Chen|C|', 'Wu|Xia|X|', 'Cao|Yihan|Y|', 'Zeng|Yueping|Y|', 'Zhang|Weihong|W|', 'Zhang|Shuo|S|', 'Liu|Yuehua|Y|', 'Jin|Hongzhong|H|', 'Zhang|Wen|W|', 'Li|Li|L|']
D020083:Acquired Hyperostosis Syndrome D000328:Adult D017668:Age of Onset D002681:China D015331:Cohort Studies D003430:Cross-Sectional Studies D000068800:Etanercept D005260:Female D006801:Humans D000069285:Infliximab D008297:Male D008875:Middle Aged D011565:Psoriasis D012074:Remission Induction D014409:Tumor Necrosis Factor-alpha
SAPHO syndrome Side effects Palmoplantar pustulosis Age of onset Psoriasiform lesions Tumor necrosis factor-α inhibitor